Singapore markets open in 3 hours 12 minutes
Straits Times Index
3,204.82 +2.01 (+0.06%) S&P 500
4,320.06 -9.94 (-0.23%) Dow
33,963.84 -106.56 (-0.31%) Nasdaq
13,211.81 -12.19 (-0.09%) Bitcoin USD
26,500.69 -75.04 (-0.28%) CMC Crypto 200
565.87 -2.18 (-0.38%)
Ultragenyx Pharmaceutical Inc. (0LIF.L)
LSE - LSE Delayed Price. Currency in USD
Add to watchlist
At close: 04:44PM BST
| Previous close | 36.58 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 281 |
| Market cap | 20.822M |
| Beta (5Y monthly) | 0.87 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.87 |
| Earnings date | 31 Oct 2023 - 06 Nov 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksUltragenyx (RARE) Q2 Loss Wider Than Expected, Revenues Beat
Ultragenyx (RARE) reports mixed second-quarter 2023 results, maintaining its 2023 financial guidance. The company's pipeline progress is also on track.
ZacksUltragenyx (RARE) Doses First Patients in Bone Disease Studies
Ultragenyx (RARE) announces dosing the first patients in its phase III studies evaluating setrusumab (UX143) in young adult and pediatric patients with osteogenesis imperfecta.
ZacksUltragenyx's (RARE) GTX-102 Gets FDA Nod for Uniform Dosing
Ultragenyx (RARE) stock climbs 5% after the FDA agrees to a protocol amendment to the phase I/II study of GTX-102 in pediatric patients with Angelman syndrome.
© 2023 Yahoo. All rights reserved.
